Researchers Found an Indicator of Severity of COVID-19. Soluble Circulating Protein May Be the Clue.

A new study published on April 30, 2020 in Journal Critical Care indicated that the protein soluble urokinase plasminogen activator receptor (suPAR) may assist researchers anticipate who is likely to have more severe COVID-19 symptoms. In other words, suPAR may be regarded as a proxy measure of COVID-19 severity.

The researchers examined data from 57 patients at Greece's University of Athens Medical School and 5 COVID-19 patients at Rush University Medical Center. They discovered that patients with greater amounts of suPAR in their blood needed intubation sooner than individuals with lower levels of suPAR.

This is the first publication to suggest that suPAR is higher in COVID-19 and may be indicative of COVID-19 severity.

This study is important not just for identifying patients who are more likely to require immediate intensive care, but also for identifying individuals who can safely manage the condition at home.

References






Comments

Popular posts from this blog

First Living Robots from Stem Cells. Are We Dreaming?

Kawasaki-like Disease is seen in Some Children with COVID-19